Clinical trials: Severe Dengue
Dengue (Virus); Fever, Sandfly, Sickle Cell Disease
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or…
- Trial name
- DREPADENGUE (NCT07000747)
- Where
- Guadeloupe
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Dengue, Dengue Fever
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01488890
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
- Where
- 7 sites in United States
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
- Trial name
- DPIV-001 (NCT01666652)
- Testing
- 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever, Pleural Effusion
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Rationale and Aims: Infection by dengue virus (DENV) causes major morbidity and mortality throughout the world. In 2012, an estimated 3.6 billion people live in areas at risk for DENV infection, including Singapore.
- Trial name
- KETODEN (NCT02673840)
- Testing
- Ketotifen
- Where
- 2 sites in Singapore
- Volunteers
- 110 people
- Sponsor
- National University Hospital, Singapore
Dengue, Severe Dengue
Dengue Serostatus Study in the Philippines
This is an observational study for 5 years, and aims to determine the risk of developing dengue among Philippine children who are eligible to receive the dengue vaccine during the DOH mass dengue vaccination, by dengue serostatus…
- Conditions
- Dengue, Severe Dengue, Dengue Fever, Virologically-confirmed Dengue
- Trial name
- NCT03465254
- Volunteers
- 2,996 people, healthy volunteers welcome
- Sponsor
- University of the Philippines
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00094705
- Testing
- rDEN2/4delta30(ME) Vaccine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Dengue
Severe Dengue in Critical Care at Villavicencio, Colombia.
Severe dengue is a cause of admission to critical care, especially in pediatric cases, and during epidemic outbreaks. Fluid support is basically the therapy offered, due to a scarcity of antiviral or immunological options to…
- Trial name
- NCT05938647
- Testing
- Risk factor: group 3, Risk factor: group 4
- Where
- 2 sites in Colombia
- Volunteers
- 199 people
- Sponsor
- Hospital Departamental de Villavicencio
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) when administered concomitantly or…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02993757
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
- Where
- 5 sites in Malaysia
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Virus, Dengue Fever
Efficacy and Safety of Dengue Vaccine in Healthy Children
The primary objective of the study was to assess the efficacy of CYD dengue vaccine after three injections in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00842530
- Testing
- CYD Dengue Vaccine, Inactivated rabies virus vaccine
- Where
- Thailand
- Volunteers
- 4,002 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Fever
Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: To describe the safety of one injection of ChimeriVax™ dengue tetravalent…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00730288
- Testing
- Chimeric dengue serotype (1, 2, 3, 4)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue, Dengue Hemorrhagic Fever
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01436396
- Testing
- Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.
- Trial name
- NCT01254422
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- Where
- 4 sites in Malaysia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Hemorrhagic Fever, Dengue Shock Syndrome
Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore
World Health Organisation (WHO) has identified Dengue as the fastest spreading mosquito-borne disease in the world. This study follows on from the National Medical Research Council STOP Dengue Translational and Clinical Research…
- Conditions
- Dengue Hemorrhagic Fever, Dengue Shock Syndrome, Severe Dengue
- Trial name
- NCT04048837
- Where
- 3 sites in Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Dengue Fever, Dengue Hemorrhagic Fever
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Primary Objectives: To evaluate safety after each CYD Dengue vaccination in terms of injection site and systemic reactogenicity. To evaluate the occurrence of Serious Adverse Events (SAEs) throughout the trial period.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus, Dengue Diseases
- Trial name
- NCT00880893
- Testing
- CYD Dengue vaccine, NaCl + influenza virus or hepatitis A vaccine
- Where
- 5 sites in Singapore
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
This study investigates the comparative efficacy of standard treatment plus Ribavirin versus standard treatment alone in preventing clinically significant hemorrhage among patients diagnosed with dengue fever.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Severe Dengue
- Trial name
- NCT06744777
- Testing
- Ribavirin, Standard Treatment
- Where
- 4 sites in Pakistan
- Volunteers
- 284 people
- Sponsor
- Khyber Medical University Peshawar
Dengue Fever
Study of HBV-001 D1 in Healthy Adults
This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and tolerability of HBV-001 D1 in healthy adult subjects.
- Trial name
- NCT00936429
- Testing
- DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hawaii Biotech, Inc.
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue
- Trial name
- NCT01374516
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 22 sites in Brazil, Colombia and 3 more
- Volunteers
- 20,869 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Hemorrhagic Fever
Gut Leakage' in Dengue
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the…
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Intestinal Disease, Ascites
- Trial name
- GLiD (NCT07602920)
- Where
- Bangladesh
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University of Oxford